Cladribine/dexamethasone

Cladribine/dexamethasone Reactions 1704, p106 - 2 Jun 2018 Various toxicities: case report A 2-year-old girl developed adrenal insufficiency following dexamethasone withdrawal. Additionally, she developed neutropenia, thrombocytopenia and anaemia following treatment with cladribine [not all routes, dosages and indications stated]. The girl, who had a history of prematurity and postural plagiocephaly was admitted to the paediatric department with afebrile generalised tonic-clonic seizure with severe hyponatraemia. She started receiving treatment with dexamethasone. The histomorphology and immunoprofile were compatible with a juvenile xanthogranuloma (JXG). Three weeks after the surgery, she developed adrenal insufficiency secondary to the dexamethasone withdrawal. One month after the surgery, an MRI was performed, which showed tumour growth with radiologically aggressive characteristics. Three months after the diagnosis of JXG, she started receiving treatment with cladribine as a second line of therapy. She received 8 cycles of IV cladribine in a daily two-hour infusion for 5 days every 3 weeks. Initially, she received cladribine 0.2 mg/kg/day, then it was increased to 0.3 mg/kg/day. She did not develop any toxicity till cycle 2. However, in the next three cycles, she developed grade 1 thrombocytopenia and grade 2 th neutropenia. After the 6 course, she developed grade 1 anaemia, grade 2 thrombocytopenia and grade 3 neutropenia [durations of treatments to reactions onsets not stated]. Subsequently, the girl’s cladribine dose was reduced to 0.2 mg/Kg/day. A repeat PET-MRI showed remarkable response with cladribine. Subsequent imaging also consistent with a good clinical response. Thereafter, she had a normal neurologic development. Her adrenal insufficiency was resolved [not all outcomes stated]. Author comment: "The patient’s clinical situation three weeks after surgery was the following: . . . adrenal insufficiency secondary to withdrawal of dexamethasone". "Our patient had a grade 3 hematological toxicity with no serious infectious events, maintaining mild thrombocytopenia during the first six months following end of [cladribine] treatment, which has currently been resolved." Areal-Hidalgo P, et al. Isolated intra-axial central nervous system juvenile xanthogranuloma (JXG). Clinical management and follow-up with PET-MRI. Pediatric Hematology Oncology Journal 3: 24-28, No. 1, Mar 2018. Available from: URL: http://doi.org/10.1016/j.phoj.2017.12.003 - Spain 803323729 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cladribine/dexamethasone

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/cladribine-dexamethasone-NeG3bEXx3Y
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46749-6
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p106 - 2 Jun 2018 Various toxicities: case report A 2-year-old girl developed adrenal insufficiency following dexamethasone withdrawal. Additionally, she developed neutropenia, thrombocytopenia and anaemia following treatment with cladribine [not all routes, dosages and indications stated]. The girl, who had a history of prematurity and postural plagiocephaly was admitted to the paediatric department with afebrile generalised tonic-clonic seizure with severe hyponatraemia. She started receiving treatment with dexamethasone. The histomorphology and immunoprofile were compatible with a juvenile xanthogranuloma (JXG). Three weeks after the surgery, she developed adrenal insufficiency secondary to the dexamethasone withdrawal. One month after the surgery, an MRI was performed, which showed tumour growth with radiologically aggressive characteristics. Three months after the diagnosis of JXG, she started receiving treatment with cladribine as a second line of therapy. She received 8 cycles of IV cladribine in a daily two-hour infusion for 5 days every 3 weeks. Initially, she received cladribine 0.2 mg/kg/day, then it was increased to 0.3 mg/kg/day. She did not develop any toxicity till cycle 2. However, in the next three cycles, she developed grade 1 thrombocytopenia and grade 2 th neutropenia. After the 6 course, she developed grade 1 anaemia, grade 2 thrombocytopenia and grade 3 neutropenia [durations of treatments to reactions onsets not stated]. Subsequently, the girl’s cladribine dose was reduced to 0.2 mg/Kg/day. A repeat PET-MRI showed remarkable response with cladribine. Subsequent imaging also consistent with a good clinical response. Thereafter, she had a normal neurologic development. Her adrenal insufficiency was resolved [not all outcomes stated]. Author comment: "The patient’s clinical situation three weeks after surgery was the following: . . . adrenal insufficiency secondary to withdrawal of dexamethasone". "Our patient had a grade 3 hematological toxicity with no serious infectious events, maintaining mild thrombocytopenia during the first six months following end of [cladribine] treatment, which has currently been resolved." Areal-Hidalgo P, et al. Isolated intra-axial central nervous system juvenile xanthogranuloma (JXG). Clinical management and follow-up with PET-MRI. Pediatric Hematology Oncology Journal 3: 24-28, No. 1, Mar 2018. Available from: URL: http://doi.org/10.1016/j.phoj.2017.12.003 - Spain 803323729 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off